These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9219250)

  • 1. Sepsis therapy still shocking.
    Nat Biotechnol; 1997 Jul; 15(7):601. PubMed ID: 9219250
    [No Abstract]   [Full Text] [Related]  

  • 2. [Non-antibiotic treatment of sepsis].
    Møller K; Kronborg G; Pedersen BK
    Ugeskr Laeger; 2000 May; 162(20):2872-5. PubMed ID: 10860425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome.
    Seitz M; Kamgang RK; Simon HU; Villiger PM
    Ann Rheum Dis; 2005 Dec; 64(12):1802-3. PubMed ID: 16284353
    [No Abstract]   [Full Text] [Related]  

  • 5. Sepsis trials. Intersection of investigation, regulation, funding, and practice.
    Bernard GR
    Am J Respir Crit Care Med; 1995 Jul; 152(1):4-10. PubMed ID: 7599855
    [No Abstract]   [Full Text] [Related]  

  • 6. New therapeutic approaches in sepsis: a critical review.
    Eidelman LA; Pizov R; Sprung CL
    Intensive Care Med; 1995 Nov; 21 Suppl 2():S269-72. PubMed ID: 8636535
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
    Strand V; Kavanaugh AF
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapies for treatment of rheumatoid arthritis.
    Piascik P
    J Am Pharm Assoc (Wash); 1997; NS37(1):14-6. PubMed ID: 9040165
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interleukin-1 receptor antagonist: a new therapeutic agent in the treatment of sepsis syndrome].
    Boermeester MA; van Leeuwen PA; Schneider AJ; Houdijk AP; Ferwerda CC; Wesdorp RI
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):337-42. PubMed ID: 7679779
    [No Abstract]   [Full Text] [Related]  

  • 11. New immunotherapies for sepsis.
    Young LS; Wenzel RP
    Proc Assoc Am Physicians; 1995 Oct; 107(3):361-4. PubMed ID: 8608423
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of recombinant interleukin-1-receptor antagonist.
    Barriere SL; Pribble JP
    Am J Hosp Pharm; 1994 May; 51(9):1253, 1257. PubMed ID: 8042646
    [No Abstract]   [Full Text] [Related]  

  • 13. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
    Paleolog EM; Young S; Stark AC; McCloskey RV; Feldmann M; Maini RN
    Arthritis Rheum; 1998 Jul; 41(7):1258-65. PubMed ID: 9663484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Such stuff as dreams are made on: mediator-directed therapy in sepsis.
    Marshall JC
    Nat Rev Drug Discov; 2003 May; 2(5):391-405. PubMed ID: 12750742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Schiff MH
    Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
    [No Abstract]   [Full Text] [Related]  

  • 16. Biologics in rheumatoid arthritis.
    Sharma PK; Hota D; Pandhi P
    J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2004 Jun; 63(3):203-10. PubMed ID: 15224223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pitfalls in the development of biologic therapy.
    Maini RN; Feldmann M
    Nat Clin Pract Rheumatol; 2007 Jan; 3(1):1. PubMed ID: 17202998
    [No Abstract]   [Full Text] [Related]  

  • 19. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis.
    Dayer JM
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii3-10. PubMed ID: 12817089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The many worlds of reducing interleukin-1.
    Dinarello CA
    Arthritis Rheum; 2005 Jul; 52(7):1960-7. PubMed ID: 15986340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.